Omekaste (Omeprazole)

Omeprazole, the active ingredient in Omekaste, is a Proton Pump Inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children. GNH USA supplies Omekaste as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omekaste as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omekaste (omeprazole) acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders.

- Gastro‑esophageal reflux disease (GERD): alleviates heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid production. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates. - NSAID‑associated ulcer prophylaxis: lowers risk of ulcer development in high‑risk patients.

Adverse reactions to omeprazole are generally mild but can vary in frequency.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea or vomiting: occasional. - Abdominal pain or flatulence: intermittent. - Constipation: occasional. - Dry mouth: mild.

Serious or Rare Side Effects: - Clostridioides difficile infection: may present with severe diarrhea. - Hypomagnesemia: can cause muscle cramps, seizures, or cardiac arrhythmia. - Acute interstitial nephritis: renal function impairment. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Bone fracture risk: long‑term use associated with decreased calcium absorption.

When prescribing Omekaste, clinicians should consider several safety aspects.

- Assess renal and hepatic function: dose adjustment may be required in impairment. - Review concomitant medications: potential for drug‑drug interactions. - Monitor long‑term users: watch for magnesium deficiency and bone health. - Use caution in pregnancy: weigh benefits against potential risks. - Avoid in patients with known hypersensitivity to omeprazole or other PPIs. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir or other protease inhibitors: decreased antiviral efficacy. - Methotrexate (high dose): increased serum concentrations, risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, monitor coagulation parameters. - Digoxin: possible increase in serum levels, observe for toxicity. - Phenytoin: reduced clearance, may require dose adjustment. - Diazepam: increased plasma concentration, monitor sedation. - Iron supplements: decreased absorption, separate administration by at least 2 hours.